<DOC>
	<DOCNO>NCT01285518</DOCNO>
	<brief_summary>This trial subject Type 2 diabetes mellitus study safety , tolerability pharmacokinetics pharmacodynamics single escalate dos PF-05231023 .</brief_summary>
	<brief_title>Safety And Tolerability Of Escalating Intravenous Doses Of PF-05231023 In Adult Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Male female subject age 30 65 year , inclusive , historical diagnosis type 2 diabetes mellitus , diagnose accord American Diabetes Association guideline . Body Mass Index ( BMI ) 25 35.5 kg/m2 , total body weight &gt; 50 kg ( 110 lb ) . HbA1c &gt; 7 % exceed 10.5 % . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) . Diagnosis Type 1 diabetes mellitus Evidence diabetic complication significant end organ damage .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Type 2 diabetes</keyword>
	<keyword>intravenous</keyword>
	<keyword>single dose</keyword>
</DOC>